Literature DB >> 14978779

Intravenous antidepressants: a review.

Nidal J Moukaddam1, Robert M A Hirschfeld.   

Abstract

Antidepressant medications have an onset of action of several weeks and have moderate efficacy. Their mode of administration is oral (p.o.). Some clinicians wondered whether intravenous (i.v.) administration would speed onset of action and increase efficacy. In this article we review controlled studies on i.v. administration of antidepressants. These include clomipramine, citalopram, and other antidepressants. Overall these studies do not support increased efficacy of i.v. over p.o.administration but there are suggestions of a faster onset of action. In one study i.v. citalopram showed superior response rates over p.o. citalopram (79% vs. 63%) in severely depressed patients at 8 weeks. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978779     DOI: 10.1002/da.10135

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  5 in total

Review 1.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 2.  The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments.

Authors:  Rodrigo Machado-Vieira; Jacqueline Baumann; Cristina Wheeler-Castillo; David Latov; Ioline D Henter; Giacomo Salvadore; Carlos A Zarate
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-06

Review 3.  EMSAM (deprenyl patch): how a promising antidepressant was underutilized.

Authors:  Gregory M Asnis; Margaret A Henderson
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-06       Impact factor: 2.570

4.  Effects of Citalopram on Cue-Induced Alcohol Craving and Thalamic D2/3 Dopamine Receptor Availability.

Authors:  Todd Zorick; Kyoji Okita; Mark A Mandelkern; Edythe D London; Arthur L Brody
Journal:  Int J Neuropsychopharmacol       Date:  2019-04-01       Impact factor: 5.176

5.  Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.

Authors:  Sanne Y Smith-Apeldoorn; Jolien K E Veraart; Jeanine Kamphuis; Antoinette D I van Asselt; Daan J Touw; Marije Aan Het Rot; Robert A Schoevers
Journal:  BMC Psychiatry       Date:  2019-11-29       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.